Latest Emtricitabine Stories
BRIDGEWATER, N.J., Oct. 22 /PRNewswire/ -- The FDA has granted PREZISTA (darunavir) tablets, a protease inhibitor, approval for an expanded indication for once-daily dosing as part of HIV combination therapy in treatment-naive adults (those who have never taken HIV medication before).
Gilead Sciences has announced that the FDA has granted marketing approval for Viread for the treatment of chronic hepatitis B, a liver disease caused by the hepatitis B virus. Viread is now also indicated for the treatment of chronic hepatitis B in adults.
Ardea Biosciences has presented positive data from its completed Phase IIa proof-of-concept monotherapy study of RDEA806, the company's investigational non-nucleoside reverse transcriptase inhibitor for patients with human immunodeficiency virus, demonstrating robust antiviral activity with a well-tolerated profile.
MEXICO CITY, Aug.
MEXICO CITY and SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.
Please replace the release with the following corrected version due to multiple revisions.
MEXICO CITY, Aug.
MEXICO CITY, Aug. 5 /PRNewswire/ -- New phase IIb data from Tibotec Pharmaceuticals Ltd.
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection.
YARDLEY, Pa., July 17 /PRNewswire/ -- Tibotec Pharmaceuticals Ltd. announced today that two major phase III efficacy trials examining TMC278, its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in treatment-naive adults with HIV-1, are now recruiting patients.
- Withering but not falling off, as a blossom that persists on a twig after flowering.